Advertisement

Comparative Epidemiology of Resistant Hypertension in Chronic Kidney Disease and the General Hypertensive Population

      Summary

      Until a few years ago, information regarding the epidemiology of resistant hypertension was obtained from indirect sources, such as cross-sectional studies on hypertension control in large cohorts from tertiary hypertension centers and outcome trials in hypertension. During the past 3 years, however, large population-based studies have provided direct epidemiologic data on resistant hypertension and estimated its prevalence at 8% to 12% of adult patients with hypertension. Chronic kidney disease (CKD), in particular, has been long considered a frequent underlying cause of resistant hypertension, however, recently, direct epidemiologic data for this entity in patients with CKD were brought to light again, suggesting an even higher prevalence of resistant hypertension (approximately 20%-35%) among such individuals. Furthermore, recent prospective cohort studies have suggested incident resistant hypertension to be associated with increased cardiovascular and renal risk in both the general hypertensive population and patients with CKD. This article discusses currently available data on epidemiology of resistant hypertension, providing a comparative overview of its prevalence, incidence, and prognosis in these two populations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • Cushman W.C.
        • Green L.A.
        • Izzo Jr, J.L.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • Mancia G.
        • Fagard R.
        • Narkiewicz K.
        • Redon J.
        • Zanchetti A.
        • Bohm M.
        • et al.
        2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        J Hypertens. 2013;31. 2013; : 1281-1357
        • Lim S.S.
        • Vos T.
        • Flaxman A.D.
        • Danaei G.
        • Shibuya K.
        • Adair-Rohani H.
        • et al.
        A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
        Lancet. 2012; 380: 2224-2260
        • Perkovic V.
        • Huxley R.
        • Wu Y.
        • Prabhakaran D.
        • MacMahon S.
        The burden of blood pressure-related disease: a neglected priority for global health.
        Hypertension. 2007; 50: 991-997
      1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
        Am J Kidney Dis. 2004; 43: S1-290
        • Fox C.S.
        • Larson M.G.
        • Leip E.P.
        • Culleton B.
        • Wilson P.W.
        • Levy D.
        Predictors of new-onset kidney disease in a community-based population.
        JAMA. 2004; 291: 844-850
        • Cutler J.A.
        • Sorlie P.D.
        • Wolz M.
        • Thom T.
        • Fields L.E.
        • Roccella E.J.
        Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004.
        Hypertension. 2008; 52: 818-827
        • Guo F.
        • He D.
        • Zhang W.
        • Walton R.G.
        Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010.
        J Am Coll Cardiol. 2012; 60: 599-606
        • Sarafidis P.A.
        • Li S.
        • Chen S.C.
        • Collins A.J.
        • Brown W.W.
        • Klag M.J.
        • et al.
        Hypertension awareness, treatment, and control in chronic kidney disease.
        Am J Med. 2008; 121: 332-340
        • Saydah S.H.
        • Fradkin J.
        • Cowie C.C.
        Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.
        JAMA. 2004; 291: 335-342
        • Dahlof B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • Julius S.
        • Beevers G.
        • de Faire U.
        • et al.
        Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Jamerson K.
        • Weber M.A.
        • Bakris G.L.
        • Dahlof B.
        • Pitt B.
        • Shi V.
        • et al.
        Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
        N Engl J Med. 2008; 359: 2417-2428
        • Pepine C.J.
        • Handberg E.M.
        • Cooper-DeHoff R.M.
        • Marks R.G.
        • Kowey P.
        • Messerli F.H.
        • et al.
        A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
        JAMA. 2003; 290: 2805-2816
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • Goff D.C.
        • Murphy T.P.
        • Toto R.D.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Hypertension. 2008; 51: 1403-1419
        • Sarafidis P.A.
        • Georgianos P.
        • Bakris G.L.
        Resistant hypertension--its identification and epidemiology.
        Nat Rev Nephrol. 2013; 9: 51-58
        • Sarafidis P.A.
        • Bakris G.L.
        Resistant hypertension: an overview of evaluation and treatment.
        J Am Coll Cardiol. 2008; 52: 1749-1757
        • Daugherty S.L.
        • Powers J.D.
        • Magid D.J.
        • Tavel H.M.
        • Masoudi F.A.
        • Margolis K.L.
        • et al.
        Incidence and prognosis of resistant hypertension in hypertensive patients.
        Circulation. 2012; 125: 1635-1642
        • Egan B.M.
        • Zhao Y.
        • Axon R.N.
        • Brzezinski W.A.
        • Ferdinand K.C.
        Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.
        Circulation. 2011; 124: 1046-1058
        • Persell S.D.
        Prevalence of resistant hypertension in the United States, 2003-2008.
        Hypertension. 2011; 57: 1076-1080
        • De Nicola L.
        • Gabbai F.B.
        • Agarwal R.
        • Chiodini P.
        • Borrelli S.
        • Bellizzi V.
        • et al.
        Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients.
        J Am Coll Cardiol. 2013; 61: 2461-2467
        • Drexler Y.R.
        • Bomback A.S.
        Definition, identification and treatment of resistant hypertension in chronic kidney disease patients.
        Nephrol Dial Transplant. 2014; 29: 1327-1335
        • Tanner R.M.
        • Calhoun D.A.
        • Bell E.K.
        • Bowling C.B.
        • Gutierrez O.M.
        • Irvin M.R.
        • et al.
        Prevalence of apparent treatment-resistant hypertension among individuals with CKD.
        Clin J Am Soc Nephrol. 2013; 8: 1583-1590
        • Sarafidis P.A.
        Epidemiology of resistant hypertension.
        J Clin Hypertens (Greenwich). 2011; 13: 523-528
        • Hajjar I.
        • Kotchen T.A.
        Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.
        JAMA. 2003; 290: 199-206
        • Wolf-Maier K.
        • Cooper R.S.
        • Kramer H.
        • Banegas J.R.
        • Giampaoli S.
        • Joffres M.R.
        • et al.
        Hypertension treatment and control in five European countries, Canada, and the United States.
        Hypertension. 2004; 43: 10-17
        • Sarafidis P.A.
        • Sharpe C.C.
        • Wood E.
        • Blacklock R.
        • Rumjon A.
        • Al Yassin A.
        • et al.
        Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease.
        Nephron Clin Pract. 2012; 120: c147-c155
        • De Nicola L.
        • Borrelli S.
        • Gabbai F.B.
        • Chiodini P.
        • Zamboli P.
        • Iodice C.
        • et al.
        Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease.
        Kidney Blood Press Res. 2011; 34: 58-67
        • Garg J.P.
        • Elliott W.J.
        • Folker A.
        • Izhar M.
        • Black H.R.
        Resistant hypertension revisited: a comparison of two university-based cohorts.
        Am J Hypertens. 2005; 18: 619-626
        • Yakovlevitch M.
        • Black H.R.
        Resistant hypertension in a tertiary care clinic.
        Arch Intern Med. 1991; 151: 1786-1792
        • McAdam-Marx C.
        • Ye X.
        • Sung J.C.
        • Brixner D.I.
        • Kahler K.H.
        Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting.
        Clin Ther. 2009; 31: 1116-1123
        • Brambilla G.
        • Bombelli M.
        • Seravalle G.
        • Cifkova R.
        • Laurent S.
        • Narkiewicz K.
        • et al.
        Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study.
        J Hypertens. 2013; 31: 2018-2024
        • Gupta A.K.
        • Nasothimiou E.G.
        • Chang C.L.
        • Sever P.S.
        • Dahlof B.
        • Poulter N.R.
        Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
        J Hypertens. 2011; 29: 2004-2013
        • de la S.A.
        • Banegas J.R.
        • Oliveras A.
        • Gorostidi M.
        • Segura J.
        • de la Cruz J.J.
        • et al.
        Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs.
        J Hypertens. 2012; 30: 1211-1216
        • Muxfeldt E.S.
        • Bloch K.V.
        • Nogueira A.R.
        • Salles G.F.
        Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension.
        Blood Press Monit. 2003; 8: 181-185
        • Pierdomenico S.D.
        • Lapenna D.
        • Bucci A.
        • Di Tommaso R.
        • Di Mascio R.
        • Manente B.M.
        • et al.
        Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.
        Am J Hypertens. 2005; 18: 1422-1428
        • Cuspidi C.
        • Macca G.
        • Sampieri L.
        • Michev I.
        • Salerno M.
        • Fusi V.
        • et al.
        High prevalence of cardiac and extracardiac target organ damage in refractory hypertension.
        J Hypertens. 2001; 19: 2063-2070
        • Muxfeldt E.S.
        • Cardoso C.R.
        • Salles G.F.
        Prognostic value of nocturnal blood pressure reduction in resistant hypertension.
        Arch Intern Med. 2009; 169: 874-880
        • Muxfeldt E.S.
        • Cardoso C.R.
        • Dias V.B.
        • Nascimento A.C.
        • Salles G.F.
        Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension.
        J Hypertens. 2010; 28: 1547-1553
        • Salles G.F.
        • Cardoso C.R.
        • Muxfeldt E.S.
        Prognostic influence of office and ambulatory blood pressures in resistant hypertension.
        Arch Intern Med. 2008; 168: 2340-2346
        • Borrelli S.
        • De Nicola L.
        • Stanzione G.
        • Conte G.
        • Minutolo R.
        Resistant hypertension in nondialysis chronic kidney disease.
        Int J Hypertens. 2013; 929183: 2013
        • Agarwal R.
        Resistant hypertension and the neglected antihypertensive: sodium restriction.
        Nephrol Dial Transplant. 2012; 27: 4041-4045
        • Pickering T.G.
        Arterial stiffness as a cause of resistant hypertension?.
        J Clin Hypertens (Greenwich). 2007; 9: 390-395
        • Sowers J.R.
        • Whaley-Connell A.
        • Epstein M.
        Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
        Ann Intern Med. 2009; 150: 776-783
        • Parati G.
        • Stergiou G.S.
        • Asmar R.
        • Bilo G.
        • de Leeuw P.
        • Imai Y.
        • et al.
        European Society of Hypertension practice guidelines for home blood pressure monitoring.
        J Hum Hypertens. 2010; 24: 779-785
        • Basile J.
        • Neutel J.
        Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy.
        Ther Adv Cardiovasc Dis. 2010; 4: 119-127
        • Oliveria S.A.
        • Lapuerta P.
        • McCarthy B.D.
        • L׳Italien G.J.
        • Berlowitz D.R.
        • Asch S.M.
        Physician-related barriers to the effective management of uncontrolled hypertension.
        Arch Intern Med. 2002; 162: 413-420
        • Pickering T.G.
        • Gerin W.
        • Schwartz A.R.
        What is the white-coat effect and how should it be measured?.
        Blood Press Monit. 2002; 7: 293-300
        • Muxfeldt E.S.
        • Bloch K.V.
        • Nogueira A.R.
        • Salles G.F.
        True resistant hypertension: is it possible to be recognized in the office?.
        Am J Hypertens. 2005; 18: 1534-1540
        • Obara T.
        • Ohkubo T.
        • Mano N.
        • Yaegashi N.
        • Kuriyama S.
        • Imai Y.
        Subtypes of resistant hypertension based on out-of-office blood pressure measurement.
        Hypertension. 2011; 58: e28
        • de la Sierra A.
        • Segura J.
        • Banegas J.R.
        • Gorostidi M.
        • de la Cruz J.J.
        • Armario P.
        • et al.
        Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.
        Hypertension. 2011; 57: 898-902
        • Gorostidi M.
        • Sarafidis P.A.
        • de la S.A.
        • Segura J.
        • de la Cruz J.J.
        • Banegas J.R.
        • et al.
        Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain.
        Am J Kidney Dis. 2013; 62: 285-294
        • Irvin M.R.
        • Shimbo D.
        • Mann D.M.
        • Reynolds K.
        • Krousel-Wood M.
        • Limdi N.A.
        • et al.
        Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.
        J Clin Hypertens (Greenwich). 2012; 14: 694-700
        • Mazzaglia G.
        • Mantovani L.G.
        • Sturkenboom M.C.
        • Filippi A.
        • Trifiro G.
        • Cricelli C.
        • et al.
        Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.
        J Hypertens. 2005; 23: 2093-2100
        • Van Wijk B.L.
        • Klungel O.H.
        • Heerdink E.R.
        • de Boer A.
        Rate and determinants of 10-year persistence with antihypertensive drugs.
        J Hypertens. 2005; 23: 2101-2107
        • Bangalore S.
        • Ley L.
        Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations.
        Expert Opin Pharmacother. 2012; 13: 345-355
        • Salahuddin A.
        • Mushtaq M.
        • Materson B.J.
        Combination therapy for hypertension 2013: an update.
        J Am Soc Hypertens. 2013; 7: 401-407